About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment
of morbidity and mortality associated with exposure to chemical nerve
-- RypVax(TM) - a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit http://www.PharmAthene.com.
Statement on Cautionary Factors for Medarex
Except for the historical information presented herein, matters
discussed herein may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved